Hybrid ELISA: Simple and specific one-tier assay for Lyme disease
混合 ELISA:针对莱姆病的简单而特异的一层检测
基本信息
- 批准号:10758919
- 负责人:
- 金额:$ 102.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-03-06 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:AccountingAlgorithmsAntibiotic ResistanceAntibiotic TherapyAntibioticsAntibodiesAntigensAreaAttentionBacterial AntigensBacterial InfectionsBindingBiological AssayBloodBorreliaBorrelia burgdorferiChronic DiseaseClinicalClinical ResearchCommunicable DiseasesDevelopmentDiagnosisDiagnosticDiagnostic testsDiseaseEnzyme-Linked Immunosorbent AssayEpitopesEuropean UnionEvaluationExanthemaEyeFormulationGeographyGovernmentGrantGrowthHybridsImmunochemistryImmunoglobulin GImmunoglobulin MIndividualInfectionLaboratoriesLegitimacyLocationLyme DiseaseLyme disease diagnosisMarketingMedicalMethodologyMethodsMidwestern United StatesNatureNew EnglandOrder SpirochaetalesPatientsPeptidesPerformancePersonsPhasePhysiciansPredictive ValuePreparationProceduresProcessProteinsProtocols documentationPublic HealthReagentRecombinant ProteinsRecommendationRecording of previous eventsReproducibilityResearch DesignRestRiskRisk FactorsRunningSamplingScreening ResultSensitivity and SpecificitySerologySerology testSerumServicesSiteSpecificityStep TestsSymptomsTest ResultTestingTick-Borne DiseasesTimeTranslationsUnited StatesValidationVector-transmitted infectious diseaseWestern Blottingantibody detectionassay developmentclinical diagnosiscommercial launchcostcross reactivitydiagnostic assayerythema migransin-vitro diagnosticsmanufacturenovelprospectiveprototyperesearch clinical testingscreeningsynthetic peptide
项目摘要
Abstract
Lyme disease, caused by infection with the spirochete Borrelia burgdorferi or closely related species, is the most
common vector-borne disease in the United States, accounting for nearly 500,000 infections per year according
to recent public health estimates. It is also one of the few infectious diseases that requires a two-step laboratory
testing protocol, comprising a screening assay, typically ELISA, followed by a confirmatory immunoblot. This
protocol is followed where the disease has progressed beyond the hallmark erythema migrans rash, or the rash
cannot be identified, and symptoms or history suggest Lyme disease. The two-step protocol is a result of the
poor specificity of most Lyme screening tests, which lead to a high false positive rate. This in turn is due to the
cross-reactive nature of many bacterial antigens, combined with the limitations of conventional ELISA
immunochemistry. In principle, a confirmatory result must be obtained prior to initiating treatment, but in practice,
the multi-day delay that is often incurred in this process frequently leads physicians to prescribe antibiotic
treatment in the absence of definitive lab results. As the vast majority of the more than three million annual Lyme
tests in the U.S. are carried out on individuals who are ultimately found not to have Lyme disease, this practice
leads to the unnecessary prescription and use of antibiotics, contributing to the growth of antibiotic resistance
which has become a significant threat to public health. A first step test with significantly higher specificity would
avoid the need for a second step test and enable clinicians to make informed treatment decisions in a timely
manner, based on credible test results.
This project is aimed at bringing about a significant change in medical practice by reducing Lyme testing from
the current two-step process to a one-step process. To achieve this objective, we have developed a novel ELISA
methodology for Lyme antibody detection that enables exceptionally high assay specificity. The test is based
on well-established, highly specific and sensitive Borrelia antigens in a unique immunochemical format. The
novel ELISA immunochemistry eliminates almost all non-specific reactivity, yielding results comparable in
specificity but higher in sensitivity than those obtained with the conventional two-tier testing protocol.
Consequently, this assay promises to deliver a one-step testing solution for Lyme disease, at a time when
alternatives to the original two-step method are gaining legitimacy at the scientific as well as regulatory level.
In Phase I, we developed a prototype ELISA assay, proving feasibility by demonstrating higher sensitivity and
equivalent specificity on retrospective samples comprising Lyme patients and controls, in comparison with two-
tier testing results. In Phase II, we will complete development of the assay into a commercial product, carry out
prospective and retrospective clinical studies and submit a 510(k) application to FDA for use of the ELISA as a
one-step test for Lyme disease, enabling commercial launch upon approval.
摘要
莱姆病,由感染螺旋体伯氏疏螺旋体或密切相关的物种,是最
在美国常见的病媒传播疾病,据统计,
最近的公共卫生评估。它也是为数不多的需要实验室两步走的传染病之一
测试方案,包括筛选测定,通常是ELISA,然后是确认性免疫印迹。这
当疾病进展超过标志性游走性红斑皮疹或皮疹时,
不能确定,症状或病史提示莱姆病。两步协议是一个结果,
大多数莱姆病筛查试验的特异性差,导致假阳性率高。这反过来又是由于
许多细菌抗原的交叉反应性质,结合常规ELISA的局限性
免疫化学原则上,在开始治疗之前必须获得确认结果,但在实践中,
在这一过程中经常发生的多日延迟常常导致医生开抗生素处方
在没有明确的实验室结果的情况下进行治疗。作为每年超过三百万的莱姆中的绝大多数
在美国,测试是在最终发现没有莱姆病的人身上进行的,这种做法
导致不必要的处方和使用抗生素,导致抗生素耐药性的增长
这已经成为对公众健康的重大威胁。具有显著更高特异性的第一步测试将
避免了第二步测试的需要,并使临床医生能够及时做出明智的治疗决定。
以可靠的测试结果为基础。
该项目旨在通过减少莱姆病检测,
将目前的两步法改为一步法。为了实现这一目标,我们开发了一种新的ELISA
莱姆病抗体检测的方法,使异常高的测定特异性。测试是基于
在一个独特的免疫化学形式的良好建立,高度特异性和敏感的疏螺旋体抗原。的
新型ELISA免疫化学消除了几乎所有的非特异性反应,
特异性,但灵敏度高于传统的两级测试方案。
因此,该检测方法有望为莱姆病提供一步式检测解决方案,
在科学和监管层面,替代最初两步法的方法正获得合法性。
在第一阶段,我们开发了一种原型ELISA测定法,通过展示更高的灵敏度和更高的灵敏度来证明其可行性。
与两种方法相比,对包括莱姆病患者和对照组的回顾性样本的特异性相当,
层测试结果。在第二阶段,我们将完成检测试剂盒的商业化开发,
前瞻性和回顾性临床研究,并向FDA提交510(k)申请,以使用ELISA作为
莱姆病的一步测试,批准后即可进行商业投放。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew E. Levin其他文献
Evaluation of a sequential enzyme immunoassay testing algorithm for Lyme disease demonstrates lack of test independence but high diagnostic specificity.
对莱姆病序贯酶免疫分析测试算法的评估表明缺乏测试独立性,但诊断特异性较高。
- DOI:
- 发表时间:
2018 - 期刊:
- 影响因子:2.9
- 作者:
G. Wormser;Claudia R. Molins;Andrew E. Levin;Susan C. Lipsett;L. Nigrovic;M. Schriefer;J. Branda - 通讯作者:
J. Branda
The Babesia observational antibody (BAOBAB) study: A cross-sectional evaluation of Babesia in two communities in Kilosa district, Tanzania
巴贝虫观察性抗体 (BAOBAB) 研究:坦桑尼亚基洛萨区两个社区巴贝虫横断面评估
- DOI:
10.1371/journal.pntd.0007632 - 发表时间:
2019 - 期刊:
- 影响因子:3.8
- 作者:
E. Bloch;Z. Mrango;M. Kasubi;Jerusha Weaver;Aleksandra Mihailovic;B. Munoz;A. Weimer;Andrew E. Levin;L. Tonnetti;J. Linnen;V. Brès;D. Norris;G. Carpi;S. West - 通讯作者:
S. West
Frequency and magnitude of seroreactivity to <em>Babesia microti</em> in 245 patients diagnosed by PCR in New York State
- DOI:
10.1016/j.diagmicrobio.2020.115008 - 发表时间:
2020-05-01 - 期刊:
- 影响因子:
- 作者:
Susan Madison-Antenucci;Gary P. Wormser;Andrew E. Levin;Susan J. Wong - 通讯作者:
Susan J. Wong
Andrew E. Levin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew E. Levin', 18)}}的其他基金
Point-of-care diagnostic test for T. cruzi (Chagas) infection
克氏锥虫(恰加斯)感染的即时诊断测试
- 批准号:
10603665 - 财政年份:2023
- 资助金额:
$ 102.5万 - 项目类别:
Development of an ELISA for serosurveillance of human hookworm
开发用于人类钩虫血清监测的 ELISA
- 批准号:
10697222 - 财政年份:2023
- 资助金额:
$ 102.5万 - 项目类别:
Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients
用于诊断癫痫患者神经囊尾蚴病的快速护理点检测
- 批准号:
9909230 - 财政年份:2020
- 资助金额:
$ 102.5万 - 项目类别:
Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients
用于诊断癫痫患者神经囊尾蚴病的快速护理点检测
- 批准号:
10084274 - 财政年份:2020
- 资助金额:
$ 102.5万 - 项目类别:
Rapid Point-of-Care Assay for Diagnosis of Neurocysticercosis in Seizure Patients
用于诊断癫痫患者神经囊尾蚴病的快速护理点检测
- 批准号:
10699435 - 财政年份:2020
- 资助金额:
$ 102.5万 - 项目类别:
Hybrid ELISA: Simple and specific one-tier assay for Lyme disease
混合 ELISA:针对莱姆病的简单而特异的一层检测
- 批准号:
9886194 - 财政年份:2019
- 资助金额:
$ 102.5万 - 项目类别:
Biomarker-Based Test of Cure for Chagas Disease
基于生物标记的恰加斯病治愈测试
- 批准号:
10761244 - 财政年份:2019
- 资助金额:
$ 102.5万 - 项目类别:
Biomarker-Based Test of Cure for Chagas Disease
基于生物标记的恰加斯病治愈测试
- 批准号:
9978716 - 财政年份:2019
- 资助金额:
$ 102.5万 - 项目类别:
Point-of-care diagnostic test for T. cruzi (Chagas) infection
克氏锥虫(恰加斯)感染的即时诊断测试
- 批准号:
9757680 - 财政年份:2018
- 资助金额:
$ 102.5万 - 项目类别:
Serologic assays for detection of Zika virus antibodies for clinical diagnosis and blood donor counseling
用于检测寨卡病毒抗体的血清学检测,用于临床诊断和献血者咨询
- 批准号:
10221519 - 财政年份:2017
- 资助金额:
$ 102.5万 - 项目类别:
相似海外基金
CAREER: Blessing of Nonconvexity in Machine Learning - Landscape Analysis and Efficient Algorithms
职业:机器学习中非凸性的祝福 - 景观分析和高效算法
- 批准号:
2337776 - 财政年份:2024
- 资助金额:
$ 102.5万 - 项目类别:
Continuing Grant
CAREER: From Dynamic Algorithms to Fast Optimization and Back
职业:从动态算法到快速优化并返回
- 批准号:
2338816 - 财政年份:2024
- 资助金额:
$ 102.5万 - 项目类别:
Continuing Grant
CAREER: Structured Minimax Optimization: Theory, Algorithms, and Applications in Robust Learning
职业:结构化极小极大优化:稳健学习中的理论、算法和应用
- 批准号:
2338846 - 财政年份:2024
- 资助金额:
$ 102.5万 - 项目类别:
Continuing Grant
CRII: SaTC: Reliable Hardware Architectures Against Side-Channel Attacks for Post-Quantum Cryptographic Algorithms
CRII:SaTC:针对后量子密码算法的侧通道攻击的可靠硬件架构
- 批准号:
2348261 - 财政年份:2024
- 资助金额:
$ 102.5万 - 项目类别:
Standard Grant
CRII: AF: The Impact of Knowledge on the Performance of Distributed Algorithms
CRII:AF:知识对分布式算法性能的影响
- 批准号:
2348346 - 财政年份:2024
- 资助金额:
$ 102.5万 - 项目类别:
Standard Grant
CRII: CSR: From Bloom Filters to Noise Reduction Streaming Algorithms
CRII:CSR:从布隆过滤器到降噪流算法
- 批准号:
2348457 - 财政年份:2024
- 资助金额:
$ 102.5万 - 项目类别:
Standard Grant
EAGER: Search-Accelerated Markov Chain Monte Carlo Algorithms for Bayesian Neural Networks and Trillion-Dimensional Problems
EAGER:贝叶斯神经网络和万亿维问题的搜索加速马尔可夫链蒙特卡罗算法
- 批准号:
2404989 - 财政年份:2024
- 资助金额:
$ 102.5万 - 项目类别:
Standard Grant
CAREER: Efficient Algorithms for Modern Computer Architecture
职业:现代计算机架构的高效算法
- 批准号:
2339310 - 财政年份:2024
- 资助金额:
$ 102.5万 - 项目类别:
Continuing Grant
CAREER: Improving Real-world Performance of AI Biosignal Algorithms
职业:提高人工智能生物信号算法的实际性能
- 批准号:
2339669 - 财政年份:2024
- 资助金额:
$ 102.5万 - 项目类别:
Continuing Grant
DMS-EPSRC: Asymptotic Analysis of Online Training Algorithms in Machine Learning: Recurrent, Graphical, and Deep Neural Networks
DMS-EPSRC:机器学习中在线训练算法的渐近分析:循环、图形和深度神经网络
- 批准号:
EP/Y029089/1 - 财政年份:2024
- 资助金额:
$ 102.5万 - 项目类别:
Research Grant